【映恩生物-B(09606.HK)关键产品DB-1310获美国FDA授予快速通道资格认定】智通财经APP讯,映恩生物-B

智通财经
Jul 22, 2025
【映恩生物-B(09606.HK)关键产品DB-1310获美国FDA授予快速通道资格认定】智通财经APP讯,映恩生物-B(09606.HK)公布,公司的关键产品DB-1310(一款靶向人表皮生长因子受体3(HER3)的抗体偶联药物(ADC”)已获美国食品药品监督管理局(FDA)授予快速通道资格认定,用于治疗接受第三代表皮生长因子受体(EGFR)酪氨酸激酶抑制剂(TKI)治疗和含铂化疗治疗期间或之后疾病进展、携带EGFR 19外显子缺失或L858R突变的晚期╱不可切除或转移性非鳞状非小细胞肺癌(nsqNSCLC)成人患者。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10